HNB
IMDX

Huntington National Bank’s Insight Molecular Diagnostics IMDX Stock Holding History

Huntington National Bank’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed – – 1803
2018
Q3 		$0 Hold
1
– – ﹤0.01% 1823
2018
Q2 		$0 Hold
1
– – ﹤0.01% 1619
2018
Q1 		$0 Hold
1
– – ﹤0.01% 1641
2017
Q4 		$0 Hold
1
– – ﹤0.01% 1674
2017
Q3 		$0 Hold
1
– – ﹤0.01% 1637
2017
Q2 		$0 Hold
1
– – ﹤0.01% 1555
2017
Q1 		$0 Hold
1
– – ﹤0.01% 1436
2016
Q4 		$0 Hold
1
– – ﹤0.01% 1484
2016
Q3 		$0 Hold
1
– – ﹤0.01% 1559
2016
Q2 		$0 Hold
1
– – ﹤0.01% 1614
2016
Q1 		$0 Buy
+1
New +$89 ﹤0.01% 1790

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WJA
Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Huntington National Bank's IMDX Position: Q4 2018 in Review

Huntington National Bank sold out of Insight Molecular Diagnostics (IMDX) in Q4 2018, closing a stake of 1 share.

Huntington National Bank first reported a position in IMDX in Q1 2016 and held it in 11 quarters. The position peaked at $0 in Q3 2018. 22 funds tracked by Wall St. Rank hold IMDX as of Q4 2018.

  • Huntington National Bank reported no remaining Insight Molecular Diagnostics position as of Q4 2018 after selling out during the quarter.
  • Huntington National Bank sold 1 Insight Molecular Diagnostics share in Q4 2018.
  • Huntington National Bank first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 11 quarters.
  • Huntington National Bank's Insight Molecular Diagnostics position peaked at $0 in Q3 2018.
  • 22 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2018.

Based on Huntington National Bank's 13F filing for Q4 2018, filed 28 Jan 2019.